Explore foreign investment strategies for 2025, the rise of private debt ETFs, and the growth of contract research organizations like Fortrea. Plus, new rules for digital payments. Read more...

Recent analyst reports have adjusted price targets for several stocks, including Fortrea, Docebo, and Silence Therapeutics. We examine these changes and their potential impact. Read more...

Recent analyst activity includes a buy rating for Jamf and lowered earnings estimates for Fortrea, Verisk, Teladoc Health, and VSE, all involving insights from William Blair. CentralReach is also exploring a sale with William Blair's assistance. Read more...

William Blair reaffirmed ratings for AvePoint and Biodesix, reiterated a "market perform" for Fortrea, and issued Q1 earnings forecast for Rocket Pharmaceuticals. Read more...